3 transcripts
ITCI
Earnings call transcript
NASDAQ
2024 Q2
7 Aug 24
for 2024, and we're confident in that guidance and in both the near term and the long-term growth prospects for CAPLYTA. As you know, from past years
ITCI
Earnings call transcript
NASDAQ
2024 Q1
7 May 24
501, coupled with lumateperone's distinct pharmacology reinforced our label expansion strategy and the long-term prospects for lumateperone across
ITCI
Earnings call transcript
NASDAQ
2023 Q2
3 Aug 23
are on lumateperone for the treatment of bipolar depression, and they are neither in our short-term clinical trials nor in our long-term clinical
- Prev
- 1
- Next